Ambulatory Blood Pressure Comparison of Amlodipine, Cilnidipine, and Azelnidipine in Hypertension: The AMCILAZ-EH Multicentre, Prospective, Observational Study
Prabhakar Dorairaj, Murugarajan Singaram, Narasingan SN, Harikrishnan Parthasarathy, Natarajan Srikant, Shanmugasundaram Somasundaram · 2026
Read Ambulatory Blood Pressure Comparison of Amlodipine, Cilnidipine, and Azelnidipine in Hypertension: The AMCILAZ-EH Multicentre, Prospective, Observational Study by Prabhakar Dorairaj, Murugarajan Singaram, Narasingan SN, Harikrishnan Parthasarathy, Natarajan Srikant, Shanmugasundaram Somasundaram (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13319494.txt.
Description
Prabhakar Dorairaj and colleagues compare, in 2026, three calcium channel blocker drugs for high blood pressure in an Indian multicentre study. Amlodipine is the established standard, while cilnidipine and azelnidipine have extra properties that might change daily pressure patterns. Real-world differences between them were uncertain.
Fifty adults with mild to moderate hypertension took one of the three drugs for eight weeks, with clinic checks and 24-hour ambulatory monitoring before and after. All three groups achieved significant pressure reductions, with no significant difference in overall 24-hour change. Awake-period readings differed slightly between two of the drugs. Target achievement, pulse rate and day-night dipping patterns were broadly comparable. The authors conclude the three options perform similarly in the short term.
Catalog record
| CREATOR | Prabhakar Dorairaj, Murugarajan Singaram, Narasingan SN, Harikrishnan Parthasarathy, Natarajan Srikant, Shanmugasundaram Somasundaram |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |